Medscape Medical News > Conference News > ECNP 2024 Kate Johnson September 23, 2024 MILAN — Psilocybin leads to a better overall outcome in the treatment of moderate to severe major depressive disorder (MDD) than the selective serotonin reuptake inhibitor (SSRI) escitalopram, results of the first long-term comparison of the two treatments suggest. “This is...